Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Noxopharm set to benefit from new data showing experimental drug Lu-PSMA-617 to become important treatment for late-stage prostate cancer

% of readers think this story is Fact. Add your two cents.


Noxopharm Ltd (ASX:NOX) welcomes news that Novartis’ experimental drug, 177Lutetium-PSMA-617 (Lu-PSMA-617), looks set to become an important new treatment for late-stage prostate cancer on the basis of new Phase 3 clinical trial data.

This has provided strong encouragement for Noxopharm given its recent LuPIN trial data showing even stronger survival outcome when the experimental radioligand Lu-PSMA-617 is combined with Veyonda®.

Novartis’ VISION study reported a median Overall Survival (mOS) of 15.3 months for Lu-PSMA-617 + standard of care versus 11.3 months for standard of care alone.

This compares with 19.7 months from the LuPIN trial that tested the combination of Lu-PSMA-617 and Veyonda® in men with end-stage mCRPC who had progressed on at least three previous lines of therapy.

Full details will be presented on Monday morning (AEST) to the Annual Meeting of the American Society of Clinical Oncology (ASCO), the foremost cancer conference in the world.

“Positive news”

NOX managing director and CEO Dr Graham Kelly said: “This result is positive news for Noxopharm for two reasons.

“The first is that it confirms that Veyonda® in combination with Lu-PSMA-617 provides a considerable survival advantage over Lu-PSMA-617 alone.

“The LuPIN mOS outcome of 19.7 months still remains the best survival outcome of any drug approved for use in men with end-stage prostate cancer including enzalutamide, abiraterone, docetaxel, cabazitaxel and now Lu-PSMA-617.

“The second is that having Lu-PSMA-617 likely to come to market as a third-line therapy provides a clear development pathway now for Veyonda® to come to market itself, with a distinct opportunity to make the Veyonda®/Lu-PSMA-617 combination a new standard of care for end-stage prostate cancer.”

Due to the strong overall survival benefit in the VISION trial of four months (15.3 vs 11.3), Noxopharm believes that it will see Lu-PSMA-617 receive marketing approval in major territories such as the US and EC with likely introduction to the market in early-2022.

Greater survival benefit demonstrated 

Noxopharm chief medical officer Dr Gisela Mautner said: “Noxopharm welcomes this news because it has a major interest in seeing Lu-PSMA-617 come to market and become a standard of care for prostate cancer.

“The company believes that the LuPIN study has demonstrated that Veyonda® has the ability to enhance the efficacy of Lu-PSMA-617, with a greater survival benefit from the combination than Lu-PSMA-617 alone.

“This well-tolerated combination therapy should increase the attractiveness of radioligand therapy for men with late-stage prostate cancer even more.”

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/951401/noxopharm-set-to-benefit-from-new-data-showing-experimental-drug-lu-psma-617-to-become-important-treatment-for-late-stage-prostate-cancer-951401.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST


Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse
Loading...

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

MOST RECENT
Load more ...

SignUp

Login

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.